Differences in killing activity of caspofungin and paradoxical growth between Candida albicans and C. krusei clinical isolates in different media

Journal of Chemotherapy

Volumn 21, Issue 1, 2009, Pages 36-41

  Varga, I ^a   Soczo G ^b   Kardos, G ^b   Kemeny Beke A ^b   Kelentey, B ^a   Marton I ^a   Majoros, László ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Candida; Caspofungin; Eagle effect; Fungicidal; Paradoxical growth; Time kill

Indexed keywords

CASPOFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN;

ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; FUNGUS GROWTH; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM FUNGICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; CANDIDA; CULTURE MEDIUM; CULTURE TECHNIQUE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; METHODOLOGY; MICROBIOLOGICAL EXAMINATION;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CELL CULTURE TECHNIQUES; CULTURE MEDIA; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS;

EID: 63049125473     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362 (9390): 1142-1151.
2. Pfaller, MA, Diekema DJ, Messer SA, Hollis RJ, and Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47(3): 1068-1071.
3. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46 (1): 150-156.
4. Sóczó G, Kardos G, Varga I, Kelentey B, Gesztelyi R, Maioros L. In vitro studies with C. tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin. Antimicrob Agents Chemother 2007; 51 (12):4474-4476.
5. Varga I, Soczo G, Kardos G, Majoros L. Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3. J Antimicrob Chemother 2008; 62 (1): 149-152.
6. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51(6): 2257-2259.
7. Sóczó G, Kardos G, McNicholas PM, Balogh E, Gergely L, Varga I, et al. Correlation of posaconazole minimum fungicidal concentration and time-kill test against nine Candida species. J Antimicrob Chemother 2007; 60 (5): 1004-1009.
8. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2002.
9. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results for standardized methods. Antimicrob Agents Chemother 1998; 42 (5):1207-1212.
10. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356 (24): 2472-2482.
11. Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45 (7): 883-893.
12. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347 (25): 2020-2029.
13. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57 (4): 705-708.
14. Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007; 59 (6): 1076-1083.
15. Kahn J N, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51 (5): 1876-1878.
16. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006; 50 (4): 1293-1297.
17. Fleischhacker M, Radacke C, Schulz B, Ruhnke M. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 2008; 27 (2): 127-131.
18. Jacobsen MD, Whyte JA, Odds FC. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob Agents Chemother 2007; 51 (5): 1882-1884.